FDA Brief

Warning letters Devices

FDA warning letter to

Exactech, Inc. dba Advita Ortho

High riskIssued Dec 19, 2025Posted Mar 10Center for Devices and Radiological Health

FDA warned Exactech/Advita Ortho over quality-system failures in Equinoxe shoulder implants found during a July 2025 Sarasota inspection.

What happened

FDA inspected Exactech's Sarasota, Florida facility from July 15 to July 25, 2025. It found the company had not adequately controlled manufacturing processes, handled nonconforming product, monitored storage environment, qualified a critical UHMWPE powder supplier, trained staff, or documented acceptance activities for Equinoxe shoulder and other implant devices.

What FDA found

  1. The firm did not adequately define process controls, specifications, and testing for UHMWPE powder and molded parts, and work instructions for shoulder components lacked clear inspection steps.

    21 CFR 820.70(a)
  2. The CAPA procedure did not treat production events as quality data, and CAPAs for storage temperature and humidity were closed as effective even though excursions continued.

    21 CFR 820.100(a)
  3. The firm lacked adequate procedures to identify and evaluate nonconforming product, including production events and work-in-process scrap.

    21 CFR 820.90(a)
  4. Environmental controls were inadequate: temperature and humidity were routinely out of limits, and backup monitoring was not followed when the system failed.

    21 CFR 820.70(c)
  5. The sole supplier of critical UHMWPE powder had not received a required on-site audit, and there was no signed quality agreement.

    21 CFR 820.50
  6. Training records lacked required QC inspection tool training, and some machining work instructions did not direct staff to the correct production procedure.

    21 CFR 820.25(b); 21 CFR 820.80(a)

What FDA wants

FDA tells the firm its responses are not adequate and to correct the cited violations. The letter notes CAPA work is scheduled through March, April, or June 2026 depending on the CAPA, but it does not state a separate response deadline in the provided text.

Who should pay attention

  • hospitals and surgeons using Equinoxe shoulder implants
  • medical-device makers that rely on supplier audits and inspection methods
  • quality teams at contract manufacturers making implant components

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk